Omeros Corp
Abierto
Sector Salud
4.23 4.44
Resumen
Variación precio
24h
Mínimo
3.99
Máximo
4.26
Ingresos | -56M |
|---|---|
BPA | -0.15 |
Próximas Ganancias | 7 nov 2024 |
|---|
Capitalización de Mercado | -9.5M 216M |
|---|---|
Apertura anterior | -0.21 |
Cierre anterior | 4.23 |
Noticias sobre sentimiento de mercado
By Acuity
58%
42%
313 / 390 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Strong Bearish Evidence
Omeros Corp Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Omeros Corp Esperado
Sentimiento
By Acuity
313 / 390 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura bajista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Omeros Corp
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.
